Role of aspartate 351 in transactivation and active conformation of estrogen receptor α

Journal of Molecular Endocrinology

Volumn 35, Issue 3, 2005, Pages 449-464

  Kim, Jeong Hoon ^a,b   Lee, Mee Hyun ^b   Kim, Byoung Jin ^b   Kim, Jun Hyun ^b   Han, Seong Jun ^b   Kim, Hak Yeop ^b   Stallcup, Michael R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b C and C Research Laboratories   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE TRANSFERASE; LEUCINE; LYSINE; PROTEIN P160; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL CULTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA BINDING; ESTROGEN BINDING; GENE MUTATION; GENETIC CONSERVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ASPARTIC ACID; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 29744462678     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01846     Document Type: Article

References (45)

1. Anghel SI, Perly V, Melancon G, Barsalou A, Chagnon S, Rosenauer A, Miller WH Jr & Mader S 2000 Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. Journal of Biological Chemistry 275 20867-20872.
2. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965-968.
3. Benko S, Love JD, Beladi M, Schwabe JW & Nagy L 2003 Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor. Journal of Biological Chemistry 278 43797-43806.
4. Bourguet W, Ruff M, Chambon P, Gronemeyer H & Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375 377-382.
5. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
6. Carlson KE, Choi I, Gee A, Katzenellenbogen BS & Katzenellenbogen JA 1997 Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36 14897-14905.
7. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ & Yamamoto KR 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes and Development 12 3343-3356.
8. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D & Renaud JP 2002 Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Molecular Cell 9 303-313.
9. Hall JM, Couse JF & Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. Journal of Biological Chemistry 276 36869-36872.
10. Heery DM, Kalkhoven E, Hoare S & Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 733-736.
11. Henttu PM, Kalkhoven E & Parker MG 1997 AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Molecular and Cellular Biology 17 1832-1839.
12. Hong H, Kohli K, Garabedian MJ & Stallcup MR 1997 GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Molecular and Cellular Biology 17 2735-2744.
13. Hong H, Yang L & Stallcup MR 1999 Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. Journal of Biological Chemistry 274 22618-22626.
14. Howell A 2000 Faslodex (ICI 182780): an oestrogen receptor downregulator. European Journal of Cancer 36 (Suppl 4) S87-S88.
15. Jordan VC & Morrow M 1999 Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine Reviews 20 253-278.
16. Kallenberger BC, Love JD, Chatterjee VK & Schwabe JW 2003 A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nature Structural Biology 10 136-140.
17. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
18. Kim JH, Li H & Stallcup MR 2003 CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Molecular Cell 12 1537-1549.
19. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925-5930.
20. Lazennec G, Ediger TR, Petz LN, Nardulli AM & Katzenellenbogen BS 1997 Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Molecular Endocrinology 11 1375-1386.
21. Levenson AS & Jordan VC 1998 The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Research 58 1872-1875.
22. Levenson AS, MacGregor Schafer JI, Bentrem DJ, Pease KM & Jordan VC 2001 Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. Journal of Steroid Biochemistry and Molecular Biology 76 61-70.
23. Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW & Jordan VC 2002 Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. Journal of Biological Chemistry 277 9189-9198.
24. Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA & Stallcup MR 1999 Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Molecular and Cellular Biology 19 6164-6173.
25. Mak HY, Hoare S, Henttu PM & Parker MG 1999 Molecular determinants of the estrogen receptor-coactivator interface. Molecular and Cellular Biology 19 3895-3903.
26. Moras D & Gronemeyer H 1998 The nuclear receptor ligand-binding domain: structure and function. Current Opinion in Cell Biology 10 384-391.
27. Nettles KW & Greene GL 2005 Ligand control of coregulator recruitment to nuclear receptors. Annual Review of Physiology 67 309-333.
28. Onate SA, Tsai SY, Tsai MJ & O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 1354-1357.
29. Osborne CK, Zhao H & Fuqua SA 2000 Selective estrogen receptor modulators: structure, function, and clinical use. Journal of Clinical Oncology 18 3172-3186.
30. Parker MG 1993 Steroid and related receptors. Current Opinion in Cell Biology 5 499-504.
31. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA & Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO Journal 18 4608-4618.
32. Scatchard G 1949 The attraction of proteins for small molecules and ions. Annals of the New York Academy of Sciences 51 660.
33. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor /coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
34. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN & Atkin SL 1999 Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Research 59 525-528.
35. Tremblay G, Tremblay A, Labrie F & Giguere V 1998 Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Research 58 877-881.
36. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
37. Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS & Kushner PJ 2000 An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. Journal of Biological Chemistry 275 37552-37558.
38. Weis KE, Ekena K, Thomas JA, Lazennec G & Katzenellenbogen BS 1996 Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Molecular Endocrinology 10 1388-1398.
39. White R, Sjoberg M, Kalkhoven E & Parker MG 1997 Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO Journal 16 1427-1435.
40. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S et al. 1997 Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138 3901-3911.
41. Wolf DM & Jordan VC 1994 The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment 31 129-138.
42. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM & Greene GL 2005 Structural basis for an unexpected mode of SERM-mediated ER antagonism. Molecular Cell 18 413-424.
43. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D & Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3 87-94.
44. Yamamoto Y, Wada O, Suzawa M, Yogiashi Y, Yano T, Kato S & Yanagisawa J 2001 The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. Journal of Biological Chemistry 276 42684-42691.
45. Zhang QX, Borg A, Wolf DM, Oesterreich S & Fuqua SA 1997 An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Research 57 1244-1249.